By Alex Lash
The dream of potent cell-killing drugs that piggyback on antibodies right into the guts of a tumor has existed nearly...
Making The Case For Antibody-Drug Conjugates
After 30 years and one market failure, antibody-drug conjugate developers have produced two strong clinical candidates, with a lot more coming in the pipeline. Can two successes turn into the next great therapeutic platform?
More from Innovation
More from In Vivo
• By
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
• By
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.